IFLR1000

CSL acquisition of Novartis vaccines

7/8/2015
Private acquisition
Select tab

$ 275 million

Completed

7/8/2015

Overview:

  • CSL, a biotechnology company, has acquired Novartis influenza vaccines from Novartis for $275 million. 

Rani Mehta - Journalist 

 

Jurisdictions:

United States
United Kingdom

Deal type:

Private acquisition

Practice area:

M&A

Industry sector:

Healthcare

Firms:
Baker McKenzie

Party: CSL (Acquirer)

Lawyer: Jane E Hobson

Linklaters

Party: Novartis (Seller)

Related deals